Evidence map›Paper›PMID 38252195›Full record

ArticleTargeted oncology2024

Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.

Silvia Camera, Margherita Rimini, Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier and 66 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

76 authors at 20 institutions in 5 countries.

Silvia Camera *Department of Oncology and Hematology, San Martino Hospital, Oristano, Italy.ORCID 0000-0001-8203-1684
Margherita Rimini *Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, via Olgettina 60, 20132, Milan, Italy. casadeigardini@gmail.com.
Federico RossariDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, via Olgettina 60, 20132, Milan, Italy.
Toshifumi TadaDepartment of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Goki SudaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Shigeo ShimoseDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Changhoon YooDepartment of Oncology, ASAN Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Jaekyung CheonDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
Fabian FinkelmeierDepartment of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Ho Yeong LimDepartment of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea.
José PresaLiver Unit-CHTMAD, Vila Real, Portugal.
Gianluca MasiUnit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
Francesca BergamoOncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Francesca SalaniUnit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
Mariarosaria MarsegliaDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Elisabeth AmadeoDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, via Olgettina 60, 20132, Milan, Italy.
Francesco VitielloDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, via Olgettina 60, 20132, Milan, Italy.
Takashi KumadaDepartment of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Hideki IwamotoDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan.
Tomoko AokiDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Hong Jae ChonDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
Vera HimmelsbachDepartment of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Massimo IavaroneDivision of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Giuseppe CabibboSection of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties PROMISE, University of Palermo, Palermo, Italy.
Margarida MontesLiver Unit-CHTMAD, Vila Real, Portugal.
Francesco Giuseppe FoschiDepartment of Internal Medicine, Ospedale di Faenza, Faenza, Italy.
Caterina VivaldiUnit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
Sara LonardiOncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Takuya ShoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Takashi NiizekiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan.
Naoshi NishidaDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Christoph SteupDepartment of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Masashi HirookaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Kazuya KariyamaDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Joji TaniDepartment of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Masanori AtsukawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Koichi TakaguchiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Ei ItobayashiDepartment of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Shinya FukunishiDepartment of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Kunihiko TsujiCenter of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Toru IshikawaDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Kazuto TajiriDepartment of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Hironori OchiHepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
Satoshi YasudaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Hidenori ToyodaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Chikara OgawaDepartment of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Takashi NishimuraDepartment of Internal medicine, Division of Gastroenterology and Hepatology, Hyogo Medical University, Nishinomiya, Japan.
Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Satoru KakizakiDepartment of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Noritomo ShimadaDivision of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Kazuhito KawataDepartment of Hepatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Atsushi HiraokaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Fujimasa TadaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Hideko OhamaGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Kazuhiro NousoDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
Akemi TsutsuiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Takuya NaganoDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Norio ItokawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Tomomi OkuboDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Michitaka ImaiDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Hisashi KosakaDepartment of Surgery, Kansai Medical University, Osaka, Japan.
Atsushi NaganumaDepartment of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Yohei KoizumiDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Shinichiro NakamuraDepartment of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Masaki KaiboriDepartment of Surgery, Kansai Medical University, Osaka, Japan.
Hiroko IijimaDepartment of Internal medicine, Division of Gastroenterology and Hepatology, Hyogo Medical University, Nishinomiya, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Mara PersanoMedical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
Silvia FotiDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, via Olgettina 60, 20132, Milan, Italy.
Fabio PiscagliaDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Mario ScartozziMedical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
Stefano CascinuDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, via Olgettina 60, 20132, Milan, Italy.
Andrea Casadei-GardiniDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, via Olgettina 60, 20132, Milan, Italy.
Vita-Salute San Raffaele University · ITEhime Prefectural Central Hospital · JPEhime University · JPGoethe University Frankfurt · DEHokkaido University · JPKagawa Prefectural Central Hospital · JPKindai University · JPKurume University · JPNippon Medical School · JPAzienda USL di Bologna · ITCHA University Bundang Medical Center · KRDireção Geral do Território · PTHimeji Red Cross Hospital · JPHyogo University · JPIstituto Oncologico Veneto · ITKagawa University · JPKansai Medical University · JPNational Hospital Organization Takasaki Medical Center · JPOgaki Municipal Hospital · JPOkayama Prefecture · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData concerning the use of lenvatinib in very old patients (≥ 80 years) are limited, although the incidence of hepatocellular carcinoma (HCC) in this patient population is constantly increasing.

objectiveThis analysis aimed to evaluate the efficacy and safety of lenvatinib in a large cohort of very old patients (≥ 80 years) with unresectable HCC. PATIENTS AND

methodsThe study was conducted on a cohort of 1325 patients from 46 centers in four Western and Eastern countries (Italy, Germany, Japan, and the Republic of Korea) who were undergoing first-line treatment with lenvatinib between July 2010 and February 2022. Patients were stratified according to age as very old (≥ 80 years) and not very old (< 80 years).

resultsThe median overall survival (OS) was 15.7 months for patients < 80 years old and 18.4 months for patients ≥ 80 years old [hazard ratio (HR) = 1.02, 95% confidence interval (CI) 0.84-1.25, p = 0.8281]. Median progression free survival (PFS) was 6.3 months for patients < 80 years old and 6.5 months for patients ≥ 80 years old (HR = 1.07, 95% CI 0.91-1.25, p = 0.3954). No differences between the two study groups were found in terms of disease control rate (DCR; 80.8% versus 78.8%; p = 0.44) and response rate (RR; 38.2% versus 37.9%; p = 0.88). Patients < 80 years old experienced significantly more hand-foot skin reaction (HFSR) grade ≥ 2 and decreased appetite grade ≥ 2. Conversely, patients ≥ 80 years old experienced significantly more fatigue grade ≥ 2. In the very old group, parameters associated with prognosis were AFP, albumin-bilirubin (ALBI) grade, Barcelona Clinic Liver Cancer (BCLC), and Child-Pugh score. BCLC stage was the only independent predictor of overall survival (OS; HR = 1.59, 95% CI 1.11-2.29, p = 0.01115).

conclusionsOur study highlights the same efficacy and safety of lenvatinib between very old and not very old patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsQuinolinesAged, 80 and overHumansPhenylurea CompoundslenvatinibPhenylurea CompoundsQuinolines

Identifiers

PMID38252195
OpenAlexW4391103492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.